Apply to trial NCT05366829

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 2Drug trial

Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

The investigators hypothesize that the addition of Tislelizumab after definitive local therapy for locally advanced inoperable Hepatocellular carcinoma (HCC) will synergize with local therapy as well as treat micro metastatic disease and improve one year progression-free survival rates for participants and optimize local control.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening